A detailed history of Fox Run Management, L.L.C. transactions in Biogen Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 7,922 shares of BIIB stock, worth $1.16 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
7,922
Holding current value
$1.16 Million
% of portfolio
0.35%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$189.07 - $236.8 $1.5 Million - $1.88 Million
7,922 New
7,922 $1.54 Million
Q1 2024

May 13, 2024

BUY
$212.02 - $267.71 $418,527 - $528,459
1,974 New
1,974 $425,000
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $655,095 - $756,982
2,380 New
2,380 $677,000
Q4 2022

Feb 07, 2023

BUY
$252.44 - $306.72 $468,023 - $568,658
1,854 New
1,854 $513,000
Q2 2022

Aug 12, 2022

BUY
$187.54 - $223.02 $235,362 - $279,890
1,255 Added 78.1%
2,862 $584,000
Q1 2022

May 10, 2022

BUY
$193.77 - $244.14 $311,388 - $392,332
1,607 New
1,607 $338,000
Q4 2021

Feb 09, 2022

SELL
$223.92 - $287.77 $158,311 - $203,453
-707 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $200,073 - $260,918
707 New
707 $200,000
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $526,823 - $727,943
-2,394 Closed
0 $0
Q3 2019

Oct 15, 2019

BUY
$217.44 - $243.88 $44,140 - $49,507
203 Added 9.27%
2,394 $557,000
Q2 2019

Jul 17, 2019

SELL
$219.29 - $241.72 $17,323 - $19,095
-79 Reduced 3.48%
2,191 $512,000
Q1 2019

Oct 17, 2019

BUY
$216.71 - $338.96 $217,793 - $340,654
1,005 Added 79.45%
2,270 $537,000
Q4 2018

Jan 15, 2019

BUY
$278.5 - $352.75 $352,302 - $446,228
1,265 New
1,265 $381,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.